These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

290 related items for PubMed ID: 21030120

  • 1. Controversies surrounding iron chelation therapy for MDS.
    Leitch HA.
    Blood Rev; 2011 Jan; 25(1):17-31. PubMed ID: 21030120
    [Abstract] [Full Text] [Related]

  • 2. Optimizing therapy for iron overload in the myelodysplastic syndromes: recent developments.
    Leitch HA.
    Drugs; 2011 Jan 22; 71(2):155-77. PubMed ID: 21275444
    [Abstract] [Full Text] [Related]

  • 3. Supportive care and chelation therapy in MDS: are we saving lives or just lowering iron?
    Leitch HA, Vickars LM.
    Hematology Am Soc Hematol Educ Program; 2009 Jan 22; ():664-72. PubMed ID: 20008252
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myélodysplasies).
    Rose C, Brechignac S, Vassilief D, Pascal L, Stamatoullas A, Guerci A, Larbaa D, Dreyfus F, Beyne-Rauzy O, Chaury MP, Roy L, Cheze S, Morel P, Fenaux P, GFM (Groupe Francophone des Myélodysplasies).
    Leuk Res; 2010 Jul 22; 34(7):864-70. PubMed ID: 20129667
    [Abstract] [Full Text] [Related]

  • 6. Impact of iron overload in myelodysplastic syndromes.
    Fenaux P, Rose C.
    Blood Rev; 2009 Dec 22; 23 Suppl 1():S15-9. PubMed ID: 20116635
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload.
    Gattermann N.
    Leuk Res; 2007 Dec 22; 31 Suppl 3():S10-5. PubMed ID: 18037413
    [Abstract] [Full Text] [Related]

  • 10. Toward resolving the unsettled role of iron chelation therapy in myelodysplastic syndromes.
    Merkel DG, Nagler A.
    Expert Rev Anticancer Ther; 2014 Jul 22; 14(7):817-29. PubMed ID: 24641787
    [Abstract] [Full Text] [Related]

  • 11. Improving clinical outcome in patients with myelodysplastic syndrome and iron overload using iron chelation therapy.
    Leitch HA.
    Leuk Res; 2007 Dec 22; 31 Suppl 3():S7-9. PubMed ID: 18037416
    [Abstract] [Full Text] [Related]

  • 12. Hematologic improvement with iron chelation therapy in myelodysplastic syndromes: Clinical data, potential mechanisms, and outstanding questions.
    Leitch HA, Gattermann N.
    Crit Rev Oncol Hematol; 2019 Sep 22; 141():54-72. PubMed ID: 31228649
    [Abstract] [Full Text] [Related]

  • 13. Improvement of iron-mediated oxidative DNA damage in patients with transfusion-dependent myelodysplastic syndrome by treatment with deferasirox.
    Kikuchi S, Kobune M, Iyama S, Sato T, Murase K, Kawano Y, Takada K, Ono K, Kaneko Y, Miyanishi K, Sato Y, Hayashi T, Takimoto R, Kato J.
    Free Radic Biol Med; 2012 Aug 15; 53(4):643-8. PubMed ID: 22705364
    [Abstract] [Full Text] [Related]

  • 14. Iron status and treatment modalities in transfusion-dependent patients with myelodysplastic syndromes.
    Delforge M, Selleslag D, Triffet A, Mineur P, Bries G, Graux C, Trullemans F, MacDonald K, Abraham I, Pluymers W, Ravoet C.
    Ann Hematol; 2011 Jun 15; 90(6):655-66. PubMed ID: 21318574
    [Abstract] [Full Text] [Related]

  • 15. The deleterious effects of iron overload in patients with myelodysplastic syndromes.
    Dreyfus F.
    Blood Rev; 2008 Dec 15; 22 Suppl 2():S29-34. PubMed ID: 19059054
    [Abstract] [Full Text] [Related]

  • 16. Iron overload and chelation therapy in myelodysplastic syndromes.
    Temraz S, Santini V, Musallam K, Taher A.
    Crit Rev Oncol Hematol; 2014 Jul 15; 91(1):64-73. PubMed ID: 24529413
    [Abstract] [Full Text] [Related]

  • 17. Red blood cell transfusion therapy and iron chelation in patients with myelodysplastic syndromes.
    Malcovati L.
    Clin Lymphoma Myeloma; 2009 Jul 15; 9 Suppl 3():S305-11. PubMed ID: 19778858
    [Abstract] [Full Text] [Related]

  • 18. Myelodysplastic syndromes: iron overload consequences and current chelating therapies.
    Greenberg PL.
    J Natl Compr Canc Netw; 2006 Jan 15; 4(1):91-6. PubMed ID: 16403408
    [Abstract] [Full Text] [Related]

  • 19. Recent advances in the understanding of iron overload in sideroblastic myelodysplastic syndrome.
    Cuijpers ML, Raymakers RA, Mackenzie MA, de Witte TJ, Swinkels DW.
    Br J Haematol; 2010 May 15; 149(3):322-33. PubMed ID: 20067561
    [Abstract] [Full Text] [Related]

  • 20. Treatment of iron overload in thalassemia.
    Cianciulli P.
    Pediatr Endocrinol Rev; 2008 Oct 15; 6 Suppl 1():208-13. PubMed ID: 19337180
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.